Clinical Pharmacology and Translational Aspects of Bispecific Antibodies

Clinical and Translational Science

Volumn 10, Issue 3, 2017, Pages 147-162

  Trivedi, A ^a   Stienen, S ^b   Zhu, M ^a   Li, H ^a   Yuraszeck, T ^a   Gibbs, J ^a,c   Heath, T ^a   Loberg, R ^a   Kasichayanula, S ^a,d  

^a AMGEN INC   (United States)

^b Amgen Research GmbH   (Germany)

^c ABBVIE INC   (United States)

^d Current Address: AbbVie Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; MONOCLONAL ANTIBODY; SOLITOMAB;

ANTIBODY STRUCTURE; CLINICAL DECISION MAKING; CLINICAL PHARMACOLOGY; COMBINATION DRUG THERAPY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IMAGING; IMMUNOGENICITY; IMMUNOTHERAPY; MODEL; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIMULATION; ANIMAL; DRUG DEVELOPMENT; IMMUNOLOGY; PATIENT SAFETY; PROCEDURES; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, BISPECIFIC; DRUG DEVELOPMENT; HUMANS; PATIENT SAFETY; RISK ASSESSMENT; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85015282576     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12459     Document Type: Review

References (85)

1. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) Codevelopment of Two or More New Investigational Drugs for Use in Combination http://wwwfdagov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/defaulthtm. June 2013.
2. Moores, S.L. et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 76, 3942–3953 (2016).
3. van Steeg T.J., Bergmann, K.R., Dimasi, N., Sachsenmeier, K.F. & Agoram, B. The application of mathematical modelling to the design of bispecific monoclonal antibodies. mAbs. 8, 585–592 (2016).
4. Byrne, H., Conroy, P.J., Whisstock, J.C. & O'Kennedy, R.J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 31, 621–632 (2013).
5. Jost, C. & Pluckthun, A. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Current Opin. Struct. Biol. 27, 102–112 (2014).
6. Huehls, A.M., Coupet, T.A. & Sentman, C.L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290–296 (2015).
7. Spiess, C., Zhai, Q. & Carter, P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67(2 Pt A), 95–106 (2015).
8. Kontermann, R.E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today. 20, 838–847 (2015).
9. Fan, G., Wang, Z., Hao, M. & Li, J. Bispecific antibodies and their applications. J. Hematol. Oncol. 8, 130 (2015).
10. Lameris, R. et al. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 92, 153–165 (2014).
11. Release, P. Bispecific antibodies market to be worth USD 4.4 billion by 2023, predicts roots analysis. Reuters. (2013).
12. Sheridan, C. Despite slow progress, bispecifics generate buzz. Nat. Biotechnol. 34, 1215–1217 (2016).
13. Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637–19646 (2010).
14. Ruf, P. et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br. J. Clin. Pharmacol. 69, 617–625 (2010)
15. Kienast, Y. et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 19, 6730–6740 (2013).
16. Wu, C. et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25, 1290–1297 (2007).
17. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).
18. Friedrich, M. et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol. Cancer Ther. 13, 1549–1557 (2014).
19. Silacci, M. et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs. 8, 141–149 (2016).
20. Doppalapudi, V.R. et al. Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 107, 22611–22616 (2010).
21. Ahene, A.B. Application and interpretation of free and total drug measurements in the development of biologics. Bioanalysis. 3, 1287–1295 (2011).
22. Zhang, Y.J., Luo, L. & Desai, D.D. Overview on biotherapeutic proteins: impact on bioanalysis. Bioanalysis. 8, 1–9 (2016).
23. Wang, Y.M., Jawa, V. & Ma, M. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis. Bioanalysis. 6, 79–87 (2014)
24. Han, Y., Guo, Q., Zhang, M., Chen, Z. & Cao, X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 182, 111–120 (2009).
25. Goldenberg, D.M., Chatal, J.F., Barbet, J., Boerman, O. & Sharkey, R.M. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther. 2, 19–31 (2007).
26. Luo, H. et al. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc. Natl. Acad. Sci. U.S.A. 112, 12806–12811 (2015).
27. Luo, H., Hong, H., Yang, S.P. & Cai, W. Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol. Pharm. 11, 1750–1761 (2014).
28. Lee, J.I., Zhang, L., Men, A.Y., Kenna, L.A. & Huang, S.M. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clinic Pharmaco. 49, 295–310 (2010).
29. Zhang X, S.C. & Grange, S. Disease-drug interaction studies of tocilizumab with cytochrome p450 substrates in vitro and in vivo. Clin. Pharmacol. Ther. 85, S59 (2009)
30. Le Vee, M., Lecureur, V., Stieger, B. & Fardel, O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab. Dispos. 37, 685–693 (2009).
31. Xu, Y. et al. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometrics Syst. Pharmacol. 4, 507–515 (2015).
32. Kenny, J.R., et al. Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop. AAPS J. 15, 933–940 (2013).
33. Agency, E.M. Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029pdf. 2007.
34. (CDER) USDoHaHSFaDACfDEaR. Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://wwwfdagov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/defaulthtm 2012.
35. Kamath, A.V. et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother. Pharmacol. 69, 1063–1069 (2012).
36. Gibiansky, L. & Gibiansky, E. Target-mediated drug disposition model for drugs that bind to more than one target. J. Pharmacokinet. Pharmacodyn. 37, 323–346 (2010).
37. U.S. Department of Health and Human Services FaDA, Center for Drug evaluation and research (CDER) guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 2005.
38. Hu, L. & Hansen, R.J. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. J. Pharm. Sci. 102, 2898–2908 (2013).
39. Friedrich, S.W. et al. Antibody-directed effector cell therapy of tumors: Analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia. 4, 449–463 (2002).
40. Apgar, J.F., Wong, J., Ryan Phennicie, R., Briskin, M. & Burke, J.M. Abstract A151: Quantitative systems pharmacology approaches accelerate lead generation and optimization of a PD-1 x TIM-3 therapeutic in immuno-oncology. Mol. Cancer Ther. 14(12 Supplement 2), A151 (2015).
41. Fitzgerald, J.B. et al. MM-141, an IGF-IR– and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR Inhibitors. Mol. Cancer Ther. 13, 410–425 (2014).
42. Huang, S. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824–833 (2013).
43. Yan, L. et al. Quantitative systems pharmacology modeling to evaluate clinical response of an anti-TNFα-anti-Ang2 bispecific antibody in rheumatoid arthritis ASCPT 2014 Annual Meeting. 2014;March 18-22, 2014(Atlanta, GA).
44. Singh, I. et al. A systems pharmacology model to characterize the effect of blinatumomab in patients with adult B precursor acute lymphoblastic leukemia. March 2014;Poster presented at the ASCPT annual meeting, Atlanta, GA.
45. Gadkar, K. et al. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. Eur. J. Pharm. Biopharm. 101, 53–61 (2016).
46. Findlay, J.W. et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21, 1249–1273 (2000).
47. Sampei, Z. et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 8, e57479 (2013).
48. Stevenson, L. et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). Bioanalysis. 6, 3355–3368 (2014).
49. Murphy, R.E. et al. Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J. Pharm. Biomed. Anal. 53, 221–227 (2010).
50. Baeuerle, P.A. & Gires, O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer. 96, 417–423 (2007).
51. Heiss, M.M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int. J. Cancer. 127, 2209–2221 (2010).
52. Seimetz, D., Lindhofer, H. & Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36, 458–467 (2010).
53. Mau-Sorensen, M. et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother. Pharmacol. 75, 1065–1073 (2015).
54. Heiss, M.M. et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 117, 435–443 (2005).
55. Burges, A. et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin. Cancer Res. 13, 3899–3905 (2007).
56. Bezan, A., Hohla, F., Meissnitzer, T. & Greil, R. Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer. 13, 618 (2013).
57. Woopen, H., Pietzner, K., Darb-Esfahani, S., Oskay-Oezcelik, G. & Sehouli, J. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med. Oncol. 29, 3416–3420 (2012).
58. Heiss, M.M. et al. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study. Clin. Cancer Res. 20, 3348–3357 (2014).
59. Atanackovic, D. et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum. Vaccin. Immunother. 9, 2533–2542 (2013).
60. Ott, M.G. et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int. J. Cancer. 130, 2195–2203 (2012).
61. Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer. 115, 98–104 (2005).
62. Dreier, T. et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer. 100, 690–697 (2002).
63. Smet, J., Mascart, F. & Schandene, L. Are the reference values of B cell subpopulations used in adults for classification of common variable immunodeficiencies appropriate for children? Clin. Immunol. 138, 266–273 (2011).
64. Tedder, T.F. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 572–577 (2009).
65. Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1, 36 (2012).
66. Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763–771 (2006).
67. Nagorsen, D., Kufer, P., Baeuerle, P.A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334–342 (2012).
68. Goebeler, M.E. et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 34, 1104–1111 (2016).
69. Zhu, M. et al. Blinatumomab, a Bispecific T-cell Engager (BiTE) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin. Pharmacokinet. 2016.
70. Baeuerle, P.A., Reinhardt, C. & Kufer, P. BiTE: A new class of antibodies that recruit T-cells. Drugs Fut. 33, 137 (2008).
71. Nagorsen, D. & Baeuerle, P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317, 1255–1260 (2011).
72. Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 119, 6226–6233 (2012).
73. Gökbuget, N.D.H. et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Oral presentation at 58th American Society of Hematology Anuual Meeting, Orlando, FL, Dec 2015. 2015.
74. Topp, M.S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66 (2015).
75. Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 127, 1410–1416 (2016).
76. Huang, S.M. et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87, 497–503 (2010).
77. Amgen Inc TO, CA, USA 2014. BlincytoTM (blinatumomab) prescribing information. 2014.
78. Brischwein, K. et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129–1143 (2006).
79. Fiedler, W.M. et al., editors. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. ASCO Annual Meeting Proceedings; 2012.
80. Amann, M. et al. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol. Immunother. 58, 95–109 (2009).
81. Amann, M. et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother. 32, 452–464 (2009).
82. Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67–81 (1999).
83. Osada, T. et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br. J. Cancer. 102, 124–133 (2010).
84. Ryan, P.C. et al. In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111). ALTEX Proc. 1, 85–87 (2012).
85. Friedrich, M. et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol. Cancer Ther. 11, 2664–2673 (2012).